Halvorsen, Sigrun
Smith, Jørgen Anton
Söderdahl, Fabian
Thuresson, Marcus
Solli, Oddvar
Ulvestad, Maria
Jonasson, Christian
Funding for this research was provided by:
Pfizer and Bristol Myers Squibb
Pfizer
Bristol Myers Squibb
Article History
Received: 22 March 2022
Accepted: 12 August 2022
First Online: 25 August 2022
Declarations
:
: The studies were conducted in accordance with the Declaration of Helsinki, local independent ethics committee/institutional review board requirements, and in compliance with the General Data Protection Regulation.Patient informed consent was not applicable to the data sources used in this study since the healthcare registries utilised are mandatory information collected on all resident Norwegians in contact with the public funded primary care system (KUHR) or having a prescription drug redeemed at pharmacy (NorPD). Informed consent was waived by the regional ethics committee sør-øst B (approval number 2018/1073 CONAN). The study was approved by the regional ethics committee sør-øst B (approval number 2018/1073 CONAN). The NorPD registry holder handled the linkage and data was delivered de-identified as per national guidelines.
: Not applicable.
: S.H did not receive any payment in connection with the development of this manuscript, but she has received financial support from Pfizer and Bristol Myers Squibb outside of the current work (speaker fees). J.A.S was a paid consultant to Pfizer and Bristol Myers Squibb in connection with the development of this manuscript. C.J was a paid consultant to Pfizer and Bristol Myers Squibb in connection with the development of the study protocol and the subsequent submissions and approval processes. F.S is an employee of Statisticon who was a paid consultant to Pfizer and Bristol Myers Squibb in connection with the development of this manuscript. M.T is an employee of Statisticon who was a paid consultant to Pfizer and Bristol Myers Squibb in connection with the development of this manuscript. O.S is an employee of Pfizer and owns shares in the company. M.U is an employee of Bristol Myers Squibb and owns shares in the company.